Isto Biologics (TSCP Portfolio) Acquires TheraCell

Isto Biologics Acquires NovaBone Products LLC

August 4, 2026

Healthcare Services

Isto Biologics announced the acquisition of NovaBone Products LLC, a developer and manufacturer of synthetic bone graft products, from Halma plc. The deal, supported by Keensight Capital, adds NovaBone’s bioactive glass technologies to Isto’s bone graft substitutes platform and expands its geographic reach and surgical end-market presence.

Keensight Capital Acquires Majority Stake in Isto Biologics

September 22, 2025

Healthcare Services

Keensight Capital has agreed to acquire a majority stake in regenerative MedTech company Isto Biologics. Thompson Street Capital Partners (TSCP) will retain a minority stake alongside Isto’s management team.

EmergentMedTech Merges with TRU Biologix

January 22, 2025

Biotechnology

EmergentMedTech announced a merger with TRU Biologix to integrate TRU Biologix's Wharton's Jelly–derived cell and tissue biologics into EmergentMedTech's regenerative medicine and aesthetics product portfolio. The deal expands EmergentMedTech's capabilities alongside its role as the exclusive U.S. distributor of NeoGen PSR, enabling delivery of advanced biologics to hundreds of clinics and clinician partners.

Envista Acquires Osteogenics Biomedical Business

May 17, 2022

Medical Devices

Envista Holdings Corporation entered into a definitive agreement to acquire Osteogenics Biomedical, Allotech LLC and OBI Biologics (collectively “Osteogenics”), a developer of regenerative dental bone grafting products sold primarily under the Cytoplast brand. The deal, subject to customary regulatory approvals and expected to close in the third quarter, expands Envista’s capabilities in regenerative solutions for periodontists, oral and maxillofacial surgeons and implant dentistry; the transaction is not subject to a financing condition or shareholder vote.

Turnstone Biologics Acquires Myst Therapeutics

January 20, 2021

Biotechnology

Turnstone Biologics Corp., a privately held clinical-stage biotechnology company, has acquired California-based Myst Therapeutics to integrate Myst’s tumor-infiltrating lymphocyte (TIL) selection and expansion platform into Turnstone’s oncolytic virus and cell therapy pipeline. The acquisition grants Turnstone full access to Myst’s R&D capabilities, development collaborations, and a TIL program with a lead candidate expected to enter the clinic soon; financial terms were not disclosed.

Thompson Street Capital Partners Acquires LifeSpan Biosciences (LSBio)

September 17, 2018

Biotechnology

Thompson Street Capital Partners (TSCP), a St. Louis-based private equity firm, has partnered with management to acquire Seattle-based LifeSpan Biosciences, Inc. (LSBio), a developer and e‑commerce distributor of antibodies, kits, proteins and related reagents for academic and pharmaceutical research. TSCP said it will support LSBio's strategy to expand its catalog and capabilities organically and via targeted acquisitions; terms were not disclosed.